Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR

Nature Reviews Clinical Oncology

Volumn 8, Issue 10, 2011, Pages 571-573

  Landi, Lorenza ^a   Cappuzzo, Federico ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; EGFR GENE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80053564599     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.135     Document Type: Article

References (10)

1. Zhou, C. C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011).
2. Gridelli, C., et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a7508 (2010).
3. Giaccone, G., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin. Cancer Res. 12, 6049-6055 (2006). (Pubitemid 44703768)
4. Thomas, M., et al. Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a7504 (2011).
5. Paez, J. G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). (Pubitemid 38720929)
6. Lee, J. S., et al. A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract PRS4]. J. Thor. Oncol. 4, S283-S284 (2009).
7. Mok, T. S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
8. Maemondo, M., et al. Gefitinib or chemotherapy for non small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
9. Mitsudomi, T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
10. Rosell, R., et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a7503 (2011).